Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Pancreatic Diseases

rosiglitazone has been researched along with Pancreatic Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA1
Balkwill, FR; Bossard, M; Candido, JB; Cook, N; Emami-Shahri, N; Hagemann, T; Maniati, E; Nedospasov, SA; Tuveson, DA1
Ahn, KO; Choi, YH; Chung, BH; Ito, S; Kim, J; Li, C; Lim, SW; Sugawara, A; Sun, BK; Yang, CW; Yang, JH; Yoon, KH1
Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A1

Other Studies

4 other study(ies) available for rosiglitazone and Pancreatic Diseases

ArticleYear
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
    Pancreas, 2009, Volume: 38, Issue:3

    Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain

2009
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:12

    Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, ras; Histones; Homeodomain Proteins; I-kappa B Kinase; Inflammation; Mice; Mice, Inbred C57BL; Neoplasm Proteins; NF-kappa B; Pancreatic Diseases; Pancreatic Neoplasms; Phosphorylation; PPAR gamma; Precancerous Conditions; Protein Processing, Post-Translational; Proto-Oncogene Mas; Receptors, Notch; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factor HES-1; Tumor Necrosis Factor-alpha

2011
Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:8

    Topics: Angiotensin II; Animals; Apoptosis; Cyclosporine; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Islets of Langerhans; Kidney; Osteopontin; Pancreatic Diseases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sialoglycoproteins; Thiazolidinediones; Transforming Growth Factor beta; Transforming Growth Factor beta1

2005
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
    Diabetes, 1998, Volume: 47, Issue:8

    Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones

1998